应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AKRO Akero Therapeutics
交易中 04-10 15:05:18 EDT
34.95
-2.41
-6.45%
最高
36.08
最低
33.18
成交量
90.03万
今开
35.88
昨收
37.36
日振幅
7.76%
总市值
27.83亿
流通市值
23.21亿
总股本
7,962万
成交额
3,122万
换手率
1.36%
流通股本
6,640万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Akero Therapeutics, Inc.2024财年实现净利润-2.52亿美元,同比减少65.79%
市场透视 · 03-08
Akero Therapeutics, Inc.2024财年实现净利润-2.52亿美元,同比减少65.79%
Akero Therapeutics, Inc.盘中异动 急速上涨5.05%报56.57美元
市场透视 · 02-04
Akero Therapeutics, Inc.盘中异动 急速上涨5.05%报56.57美元
瑞银:维持Akero Therapeutics(AKRO.US)评级,由买入调整至买入评级, 目标价由42.00美元调整至109.00美元。
金融界 · 01-31
瑞银:维持Akero Therapeutics(AKRO.US)评级,由买入调整至买入评级, 目标价由42.00美元调整至109.00美元。
异动解读 | 主要分析师升级Akero Therapeutics评级,目标价大涨80%导致股价盘中飙升5.83%
异动解读 · 01-30
异动解读 | 主要分析师升级Akero Therapeutics评级,目标价大涨80%导致股价盘中飙升5.83%
Akero Therapeutics, Inc.盘中异动 股价大涨5.00%报56.70美元
市场透视 · 01-30
Akero Therapeutics, Inc.盘中异动 股价大涨5.00%报56.70美元
B of A Securities:上调Akero Therapeutics(AKRO.US)评级,由中性调整至买入评级, 目标价由35.00美元调整至63.00美元。
金融界 · 01-30
B of A Securities:上调Akero Therapeutics(AKRO.US)评级,由中性调整至买入评级, 目标价由35.00美元调整至63.00美元。
大摩:维持Akero Therapeutics(AKRO.US)评级,由增持调整至增持评级, 目标价由46.00美元调整至96.00美元。
金融界 · 01-28
大摩:维持Akero Therapeutics(AKRO.US)评级,由增持调整至增持评级, 目标价由46.00美元调整至96.00美元。
异动解读 | 分析师看好公司前景 Akero Therapeutics盘中大涨7.89%
异动解读 · 01-28
异动解读 | 分析师看好公司前景 Akero Therapeutics盘中大涨7.89%
异动解读 | 分析师力挺Akero疗效 该股盘中大涨7.89%
异动解读 · 01-28
异动解读 | 分析师力挺Akero疗效 该股盘中大涨7.89%
Akero Therapeutics, Inc.盘中异动 早盘股价大涨7.67%
市场透视 · 01-28
Akero Therapeutics, Inc.盘中异动 早盘股价大涨7.67%
异动解读 | 多家分析师看好Akero前景 该股盘前大涨5.82%
异动解读 · 01-28
异动解读 | 多家分析师看好Akero前景 该股盘前大涨5.82%
HC Wainwright & Co.:维持Akero Therapeutics(AKRO.US)评级,由买入调整至买入评级, 目标价由50.00美元调整至72.00美元。
金融界 · 01-27
HC Wainwright & Co.:维持Akero Therapeutics(AKRO.US)评级,由买入调整至买入评级, 目标价由50.00美元调整至72.00美元。
Akero Therapeutics, Inc.盘中异动 早盘大幅拉升108.17%报54.50美元
市场透视 · 01-27
Akero Therapeutics, Inc.盘中异动 早盘大幅拉升108.17%报54.50美元
Akero Therapeutics, Inc.盘中异动 下午盘股价大跌5.04%
市场透视 · 2024-12-23
Akero Therapeutics, Inc.盘中异动 下午盘股价大跌5.04%
币安将下架 AKRO、BLZ、WRX
市场资讯 · 2024-12-18
币安将下架 AKRO、BLZ、WRX
Akero Therapeutics, Inc.盘中异动 大幅拉升5.15%报31.23美元
市场透视 · 2024-12-06
Akero Therapeutics, Inc.盘中异动 大幅拉升5.15%报31.23美元
Akero Therapeutics, Inc.2024财年第三财季实现净利润-72.71百万美元,同比减少83.33%
市场透视 · 2024-11-21
Akero Therapeutics, Inc.2024财年第三财季实现净利润-72.71百万美元,同比减少83.33%
Akero Therapeutics, Inc.盘中异动 股价大涨5.07%报34.40美元
市场透视 · 2024-11-06
Akero Therapeutics, Inc.盘中异动 股价大涨5.07%报34.40美元
Akero Therapeutics, Inc.盘中异动 急速上涨5.03%报32.38美元
市场透视 · 2024-11-01
Akero Therapeutics, Inc.盘中异动 急速上涨5.03%报32.38美元
加载更多
公司概况
公司名称:
Akero Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Akero Therapeutics, Inc.于2017年1月根据特拉华州法律成立。该公司是一家临床阶段的生物技术公司,专注于开发和商业化具有高度未满足医疗需求的严重代谢性疾病的变革性治疗方法。该公司最初的重点是非酒精性脂肪性肝炎,即NASH,一种没有任何批准疗法的疾病。NASH是一种严重的非酒精性脂肪肝疾病,或NAFLD,其特点是肝脏发生炎症和纤维化,可发展为肝硬化、肝衰竭、癌症和死亡。NASH是肝移植的主要原因。该公司的主要候选产品AKR-001正在开发,作为NASH患者的潜在治疗方法,是成纤维细胞生长因子21的类似物,即FGF21。FGF21是一种内源性表达的激素,调节全身脂质、碳水化合物和蛋白质的代谢。FGF21在保护许多类型的细胞免受各种形式的压力方面也发挥着关键作用。
发行价格:
--
{"stockData":{"symbol":"AKRO","market":"US","secType":"STK","nameCN":"Akero Therapeutics","latestPrice":34.95,"timestamp":1744311917583,"preClose":37.36,"halted":0,"volume":900328,"delay":0,"floatShares":66404930,"shares":79620128,"eps":-3.754425,"marketStatus":"交易中","change":-2.41,"latestTime":"04-10 15:05:18 EDT","open":35.88,"high":36.08,"low":33.18,"amount":31224093.501744002,"amplitude":0.077623,"askPrice":34.99,"askSize":287,"bidPrice":34.92,"bidSize":180,"shortable":0,"etf":0,"ttmEps":-3.754425,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1744315200000},"marketStatusCode":2,"adr":0,"listingDate":1561003200000,"exchange":"NASDAQ","adjPreClose":37.36,"preHourTrading":{"tag":"盘前","latestPrice":36.52,"preClose":37.36,"latestTime":"09:25 EDT","volume":24,"amount":875.9199839999999,"timestamp":1744291511438},"postHourTrading":{"tag":"盘后","latestPrice":37.35,"preClose":37.36,"latestTime":"16:09 EDT","volume":15014,"amount":560921.15,"timestamp":1744229387116},"volumeRatio":0.559707,"impliedVol":0.8168,"impliedVolPercentile":0.8964},"requestUrl":"/m/hq/s/AKRO","defaultTab":"news","newsList":[{"id":"2518447760","title":"Akero Therapeutics, Inc.2024财年实现净利润-2.52亿美元,同比减少65.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518447760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518447760?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449652,"startTime":"0","endTime":"0","summary":"3月9日,Akero Therapeutics, Inc.公布财报,公告显示公司2024财年净利润为-2.52亿美元,同比减少65.79%;其中营业收入为0.00美元,每股基本收益为-3.75美元。机构评级:截至2025年3月9日,当前有11家机构对Akero Therapeutics, Inc.目标价做出预测,其中目标均价为77.64美元,其中最低目标价为60.00美元,最高目标价为109.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000207abef97bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000207abef97bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","AKRO"],"gpt_icon":0},{"id":"2509846704","title":"Akero Therapeutics, Inc.盘中异动 急速上涨5.05%报56.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509846704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509846704?lang=zh_cn&edition=full","pubTime":"2025-02-05 02:04","pubTimestamp":1738692290,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日02时04分,Akero Therapeutics, Inc.股票出现波动,股价急速上涨5.05%。Akero Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.28%。其相关个股中,Cingulate Inc C/Wts 10/12/2026 、Azitra Inc、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大,Azitra Inc、Evaxion Biotech As、Quoin Pharmaceuticals Ltd较为活跃,换手率分别为1773.37%、967.33%、575.50%,振幅较大的相关个股有Azitra Inc、Cingulate Inc C/Wts 10/12/2026 、Quoin Pharmaceuticals Ltd,振幅分别为72.82%、57.14%、52.61%。Akero Therapeutics, Inc.公司简介:Akero Therapeutics Inc是一家临床阶段的生物技术公司,致力于开发和商业化针对严重代谢疾病的变革性治疗,具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205020450a2395090&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205020450a2395090&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","LENZ","BK4585","BK4588","AKRO"],"gpt_icon":0},{"id":"2508999044","title":"瑞银:维持Akero Therapeutics(AKRO.US)评级,由买入调整至买入评级, 目标价由42.00美元调整至109.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508999044","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508999044?lang=zh_cn&edition=full","pubTime":"2025-02-01 03:11","pubTimestamp":1738350684,"startTime":"0","endTime":"0","summary":"瑞银:维持Akero Therapeutics(AKRO.US)评级,由买入调整至买入评级, 目标价由42.00美元调整至109.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/01031147922778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","AKRO"],"gpt_icon":0},{"id":"1190094789","title":"异动解读 | 主要分析师升级Akero Therapeutics评级,目标价大涨80%导致股价盘中飙升5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190094789","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190094789?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:47","pubTimestamp":1738248436,"startTime":"0","endTime":"0","summary":"生物科技公司Akero Therapeutics(AKRO)今日盘中飙升5.83%,股价一度触及56.70美元。\n\n消息面上,美银美林将该公司的股票评级上调至买入,目标价由35美元大幅上调至63美元,参与评级的12家机构中有92%给予该股买入评级,升级幅度之大引发市场强烈反应。\n\n分析师看好Akero Therapeutics潜力股,推动了公司股价今日大涨。该公司是一家临床阶段生物科技公司,正着力开发治疗非酒精性脂肪肝炎药物AKR-001,这一未满足的大疾病市场潜力巨大,预计公司长期将获得不错的增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 主要分析师升级Akero Therapeutics评级,目标价大涨80%导致股价盘中飙升5.83%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AKRO"],"gpt_icon":0},{"id":"2507629009","title":"Akero Therapeutics, Inc.盘中异动 股价大涨5.00%报56.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507629009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507629009?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:41","pubTimestamp":1738248090,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时41分,Akero Therapeutics, Inc.股票出现异动,股价急速拉升5.00%。Akero Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.08%。Akero Therapeutics, Inc.公司简介:Akero Therapeutics Inc是一家临床阶段的生物技术公司,致力于开发和商业化针对严重代谢疾病的变革性治疗,具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130224130a234571c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130224130a234571c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKRO","BK4588","LENZ","BK4505","BK4139","BK4585"],"gpt_icon":0},{"id":"2507403206","title":"B of A Securities:上调Akero Therapeutics(AKRO.US)评级,由中性调整至买入评级, 目标价由35.00美元调整至63.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507403206","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507403206?lang=zh_cn&edition=full","pubTime":"2025-01-30 20:42","pubTimestamp":1738240955,"startTime":"0","endTime":"0","summary":"B of A Securities:上调Akero Therapeutics(AKRO.US)评级,由中性调整至买入评级, 目标价由35.00美元调整至63.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30204247909587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AKRO","LENZ"],"gpt_icon":0},{"id":"2507549176","title":"大摩:维持Akero Therapeutics(AKRO.US)评级,由增持调整至增持评级, 目标价由46.00美元调整至96.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507549176","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507549176?lang=zh_cn&edition=full","pubTime":"2025-01-29 01:31","pubTimestamp":1738085469,"startTime":"0","endTime":"0","summary":"大摩:维持Akero Therapeutics(AKRO.US)评级,由增持调整至增持评级, 目标价由46.00美元调整至96.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/29013147883501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AKRO","LENZ"],"gpt_icon":0},{"id":"1178007636","title":"异动解读 | 分析师看好公司前景 Akero Therapeutics盘中大涨7.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178007636","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178007636?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:38","pubTimestamp":1738075112,"startTime":"0","endTime":"0","summary":"生物制药公司Akero Therapeutics今日盘中大涨7.89%,引起市场广泛关注。消息面上,近期多家分析师机构相继上调了对Akero的目标股价预期。此外,摩根大通更是将目标价从49美元大幅上调至73美元,对该公司发展前景给予高度评价。分析师为何如此看好Akero?Akero主攻非酒精性脂肪性肝病的治疗领域,该领域存在着巨大的未满足医疗需求。公司核心产品近期取得了阶段性临床试验数据,数据令人鼓舞,彰显了产品的疗效和安全性,因此市场对Akero的长期成长潜力更加看好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"112d4d8d6c9067afce5bd9a0f7d276d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AKRO"],"gpt_icon":0},{"id":"1167558922","title":"异动解读 | 分析师力挺Akero疗效 该股盘中大涨7.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167558922","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167558922?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:38","pubTimestamp":1738075088,"startTime":"0","endTime":"0","summary":"生物制药股Akero Therapeutics(AKRO)今日盘中大涨7.89%,引发市场关注。\n\n多家分析师机构近期看好该公司药品前景并上调其目标股价。数据显示,卡南考德金就将AKRO的目标价从56美元大幅上调至73美元。此外,H.C.万赖特银行也将目标价从50美元上调至72美元。除此之外,摩根大通也将目标价从49美元上调至73美元,认为该公司长期前景光明。\n\n分析师的乐观评级或源自AKRO药品最新数据结果喜人,市场预期其今后能为更多肝病患者提供创新治疗。但具体分析依据目前尚不明确。不过AKRO股价大涨可见投资者备受鼓舞,对其发展信心倍增。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AKRO"],"gpt_icon":0},{"id":"2506451174","title":"Akero Therapeutics, Inc.盘中异动 早盘股价大涨7.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506451174","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506451174?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:35","pubTimestamp":1738074903,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日22时35分,Akero Therapeutics, Inc.股票出现异动,股价急速拉升7.67%。Akero Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.04%。Akero Therapeutics, Inc.公司简介:Akero Therapeutics Inc是一家临床阶段的生物技术公司,致力于开发和商业化针对严重代谢疾病的变革性治疗,具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012822350498756bfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012822350498756bfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4585","BK4588","BK4139","AKRO","LENZ"],"gpt_icon":0},{"id":"1130014646","title":"异动解读 | 多家分析师看好Akero前景 该股盘前大涨5.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130014646","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130014646?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:10","pubTimestamp":1738073433,"startTime":"0","endTime":"0","summary":"Akero Therapeutics(AKRO)盘前股价大涨5.82%,引起市场广泛关注。公司数据显示,盘前共涨7.05美元,报127.05美元。\n这一涨势或与多家分析师机构近期上调对其目标股价预期有关。据悉,Canaccord Genuity将其目标价从56美元上调至73美元,H.C. Wainwright也从50美元上调至72美元。此外,摩根大通将目标价从49美元上调至73美元,看好该公司未来前景。\n分析师为何如此看好Akero?具体原因暂时无从得知,但市场显然对这一药企发展前景抱有信心。不过该股尚处于盘前交易阶段,后市表现如何仍有待关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"112d4d8d6c9067afce5bd9a0f7d276d7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 多家分析师看好Akero前景 该股盘前大涨5.82%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AKRO"],"gpt_icon":0},{"id":"2506586202","title":"HC Wainwright & Co.:维持Akero Therapeutics(AKRO.US)评级,由买入调整至买入评级, 目标价由50.00美元调整至72.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506586202","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506586202?lang=zh_cn&edition=full","pubTime":"2025-01-28 02:51","pubTimestamp":1738003880,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:维持Akero Therapeutics(AKRO.US)评级,由买入调整至买入评级, 目标价由50.00美元调整至72.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/28025147864532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AKRO","LENZ"],"gpt_icon":0},{"id":"2506064773","title":"Akero Therapeutics, Inc.盘中异动 早盘大幅拉升108.17%报54.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506064773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506064773?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:32","pubTimestamp":1737988328,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时32分,Akero Therapeutics, Inc.股票出现波动,股价快速拉升108.17%。Akero Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.02%。Akero Therapeutics, Inc.公司简介:Akero Therapeutics Inc是一家临床阶段的生物技术公司,致力于开发和商业化针对严重代谢疾病的变革性治疗,具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127223208abba5f6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127223208abba5f6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","LENZ","BK4585","BK4588","AKRO"],"gpt_icon":0},{"id":"2493790901","title":"Akero Therapeutics, Inc.盘中异动 下午盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493790901","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2493790901?lang=zh_cn&edition=full","pubTime":"2024-12-24 04:19","pubTimestamp":1734985141,"startTime":"0","endTime":"0","summary":"北京时间2024年12月24日04时19分,Akero Therapeutics, Inc.股票出现异动,股价急速跳水5.04%。Akero Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.89%。Akero Therapeutics, Inc.公司简介:Akero Therapeutics Inc是一家临床阶段的生物技术公司,致力于开发和商业化针对严重代谢疾病的变革性治疗,具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122404190195eae001&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122404190195eae001&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4505","BK4585","BK4588","AKRO"],"gpt_icon":0},{"id":"2492711829","title":"币安将下架 AKRO、BLZ、WRX","url":"https://stock-news.laohu8.com/highlight/detail?id=2492711829","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492711829?lang=zh_cn&edition=full","pubTime":"2024-12-18 16:16","pubTimestamp":1734509760,"startTime":"0","endTime":"0","summary":"吴说获悉,据官方公告,币安将于 2024-12-25 下架 AKRO、BLZ、WRX。被移除的具体交易对为:AKRO/USDT、BLZ/BTC、BLZ/USDT、WRX/USDT。每个交易对的交易停止后,所有交易订单将被自动删除。(转自:吴说)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/blockchain/roll/2024-12-18/doc-inczwpwu0974395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4139","BK4505","AKRO","BK4588"],"gpt_icon":0},{"id":"2489125800","title":"Akero Therapeutics, Inc.盘中异动 大幅拉升5.15%报31.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489125800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2489125800?lang=zh_cn&edition=full","pubTime":"2024-12-07 00:06","pubTimestamp":1733501201,"startTime":"0","endTime":"0","summary":"北京时间2024年12月07日00时06分,Akero Therapeutics, Inc.股票出现异动,股价急速拉升5.15%。Akero Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.78%。其相关个股中,Surrozen Inc C/Wts 01/08/2031 、Cervomed Inc.、Adc Therapeutics Sa涨幅较大,Molecular Templates, Inc.、Psyence Biomedical Ltd.、Cardio Diagnostics Holdings Inc.较为活跃,换手率分别为60.99%、49.00%、48.12%,振幅较大的相关个股有Adc Therapeutics Sa、Cardio Diagnostics Holdings Inc.、Cervomed Inc.,振幅分别为40.01%、39.81%、39.61%。Akero Therapeutics, Inc.公司简介:Akero Therapeutics Inc是一家临床阶段的生物技术公司,致力于开发和商业化针对严重代谢疾病的变革性治疗,具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241207000641a1d99e06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241207000641a1d99e06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","AKRO","BK4505","BK4139","LENZ"],"gpt_icon":0},{"id":"2485141150","title":"Akero Therapeutics, Inc.2024财年第三财季实现净利润-72.71百万美元,同比减少83.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485141150","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2485141150?lang=zh_cn&edition=full","pubTime":"2024-11-22 00:00","pubTimestamp":1732204825,"startTime":"0","endTime":"0","summary":"11月22日,Akero Therapeutics, Inc.公布财报,公告显示公司2024财年第三财季净利润为-72.71百万美元,同比减少83.33%;其中营业收入为0.00美元,每股基本收益为-1.05美元。机构评级:截至2024年11月22日,当前有10家机构对Akero Therapeutics, Inc.目标价做出预测,其中目标均价为48.90美元,其中最低目标价为35.00美元,最高目标价为65.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122000035abd50d94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122000035abd50d94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKRO","LENZ"],"gpt_icon":0},{"id":"2481836869","title":"Akero Therapeutics, Inc.盘中异动 股价大涨5.07%报34.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481836869","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481836869?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:31","pubTimestamp":1730903470,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时31分,Akero Therapeutics, Inc.股票出现异动,股价急速拉升5.07%。Akero Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.91%。Akero Therapeutics, Inc.公司简介:Akero Therapeutics Inc是一家临床阶段的生物技术公司,致力于开发和商业化针对严重代谢疾病的变革性治疗,具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110622311098e40d59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110622311098e40d59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","LENZ","AKRO","BK4505","BK4585"],"gpt_icon":0},{"id":"2480688983","title":"Akero Therapeutics, Inc.盘中异动 急速上涨5.03%报32.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480688983","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2480688983?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:41","pubTimestamp":1730468481,"startTime":"0","endTime":"0","summary":"北京时间2024年11月01日21时41分,Akero Therapeutics, Inc.股票出现波动,股价急速上涨5.03%。截至发稿,该股报32.38美元/股,成交量5.6032万股,换手率0.08%,振幅4.38%。Akero Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.03%。Akero Therapeutics, Inc.公司简介:Akero Therapeutics Inc是一家临床阶段的生物技术公司,致力于开发和商业化针对严重代谢疾病的变革性治疗,具有高度医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101214121971a3d99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101214121971a3d99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4585","AKRO","BK4588","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akerotx.com","stockEarnings":[{"period":"1week","weight":-0.1094},{"period":"1month","weight":-0.1036},{"period":"3month","weight":0.4281},{"period":"6month","weight":0.2609},{"period":"1year","weight":0.5737},{"period":"ytd","weight":0.3429}],"compareEarnings":[{"period":"1week","weight":-0.0282},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0693},{"period":"6month","weight":-0.0534},{"period":"1year","weight":0.0564},{"period":"ytd","weight":-0.0639}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Akero Therapeutics, Inc.于2017年1月根据特拉华州法律成立。该公司是一家临床阶段的生物技术公司,专注于开发和商业化具有高度未满足医疗需求的严重代谢性疾病的变革性治疗方法。该公司最初的重点是非酒精性脂肪性肝炎,即NASH,一种没有任何批准疗法的疾病。NASH是一种严重的非酒精性脂肪肝疾病,或NAFLD,其特点是肝脏发生炎症和纤维化,可发展为肝硬化、肝衰竭、癌症和死亡。NASH是肝移植的主要原因。该公司的主要候选产品AKR-001正在开发,作为NASH患者的潜在治疗方法,是成纤维细胞生长因子21的类似物,即FGF21。FGF21是一种内源性表达的激素,调节全身脂质、碳水化合物和蛋白质的代谢。FGF21在保护许多类型的细胞免受各种形式的压力方面也发挥着关键作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.142297},{"month":2,"riseRate":0.5,"avgChangeRate":0.000611},{"month":3,"riseRate":0,"avgChangeRate":-0.111811},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.059513},{"month":5,"riseRate":0.2,"avgChangeRate":-0.02753},{"month":6,"riseRate":0.6,"avgChangeRate":0.063125},{"month":7,"riseRate":0.666667,"avgChangeRate":0.114884},{"month":8,"riseRate":0.833333,"avgChangeRate":0.08157},{"month":9,"riseRate":0.5,"avgChangeRate":0.279787},{"month":10,"riseRate":0.5,"avgChangeRate":-0.100766},{"month":11,"riseRate":0.666667,"avgChangeRate":0.07792},{"month":12,"riseRate":0.5,"avgChangeRate":0.076421}],"exchange":"NASDAQ","name":"Akero Therapeutics","nameEN":"Akero Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.2","shortVersion":"4.32.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Akero Therapeutics(AKRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Akero Therapeutics,AKRO,Akero Therapeutics股票,Akero Therapeutics股票老虎,Akero Therapeutics股票老虎国际,Akero Therapeutics行情,Akero Therapeutics股票行情,Akero Therapeutics股价,Akero Therapeutics股市,Akero Therapeutics股票价格,Akero Therapeutics股票交易,Akero Therapeutics股票购买,Akero Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akero Therapeutics(AKRO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Akero Therapeutics(AKRO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}